High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience

• Published in: Endocrine pathology 2024-12, Vol.35 (4), p.338-348
• Main Authors: Terry, Merryl, Nguyen, Minh P., Tang, Vivian, Guney, Ekin, Bharani, Krishna L., Dahiya, Sonika, Choutka, Ondrej, Borys, Ewa, Reis, Gerald, Blevins, Lewis, Aghi, Manish K., Kunwar, Sandeep, DeGroot, John, Raleigh, David R., Pekmezci, Melike, Bollen, Andrew W., Cha, Soonmee, Joseph, Nancy M., Perry, Arie
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aneuploidy; Cell Transformation, Neoplastic - pathology; Cerebrospinal fluid; Disease Progression; Endocrinology; Female; Gene deletion; Genetic transformation; Humans; Male; Medicine; Medicine & Public Health; Metastases; Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Metastasis - pathology; Neuroendocrine tumors; Neuroendocrine Tumors - pathology; Null cells; Oncology; p53 Protein; Pathology; Pituitary; Pituitary (anterior); Pituitary Neoplasms - genetics; Pituitary Neoplasms - pathology; PTEN protein; Sarcoma - genetics; Sarcoma - pathology; Tumors; Young Adult
• ISSN: 1046-3976; 1559-0097; 1559-0097
• DOI: 10.1007/s12022-024-09829-w

Pituitary neuroendocrine tumors (PitNET) that metastasize comprise ~ 0.2% of adenohypophyseal tumors are aggressive and are challenging to treat. However, many non-metastatic tumors are also aggressive. Herein, we review 21 specimens from 13 patients at UCSF with metastatic PitNETs (CSF or systemic, N  = 7 patients), high-grade pituitary neuroendocrine neoplasms (HG-PitNEN, N  = 4 patients), and/or PitNETs with sarcomatous transformation (PitNET-ST, N  = 5 patients). We subtyped cases using the World Health Organization (WHO) and International Agency for Research on Cancer (IARC) criteria for neuroendocrine neoplasms (NENs). Lineage subtypes included acidophil stem cell, null cell, thyrotroph, corticotroph, lactotroph, and gonadotroph tumors. The median Ki-67 labeling index was 25% (range 5–70%). Lack of p16 was seen in 3 cases, with overexpression in 2. Strong diffuse p53 immunopositivity was present in 3 specimens from 2 patients. Loss of Rb expression was seen in 2 cases, with ATRX loss in one. Molecular analysis in 4 tumors variably revealed TERT alterations, homozygous CDKN2A deletion, aneuploidy, and mutations in PTEN , TP53 , PDGFRB , and/or PIK3CA . Eight patients (62%) died of disease, 4 were alive at the last follow-up, and 1 was lost to the follow-up. All primary tumors had worrisome features, including aggressive lineage subtype, high mitotic count, and/or high Ki-67 indices. Additional evidence of high-grade progression included immunohistochemical loss of neuroendocrine, transcription factor, and/or hormone markers. We conclude that metastatic PitNET is not the only high-grade form of pituitary NEN. If further confirmed, these histopathologic and/or molecular features could provide advanced warning of biological aggressiveness and be applied towards a future grading scheme.